Home  |  Contact

Cellosaurus BL-41 (CVCL_1087)

Cell line name BL-41
Synonyms BL41; BL 41; IARC/BL41; IARC/BL 41; IARC-BL41; IARC BL41; IARC-BL-41; IARC BL 41
Accession CVCL_1087
Resource Identification Initiative To cite this cell line use: BL-41 (RRID:CVCL_1087)
Comments Part of: Cancer Cell Line Encyclopedia (CCLE) project.
Part of: COSMIC cell lines project.
Part of: MD Anderson Cell Lines Project.
From: International Agency of Research on Cancer (IARC); Lyon; France.
Characteristics: EBV-negative.
Doubling time: ~30 hours (DSMZ).
Microsatellite instability: Stable (MSS) (Sanger).
Omics: Deep exome analysis.
Omics: Deep RNAseq analysis.
Omics: DNA methylation analysis.
Omics: Deep RNAseq analysis.
Omics: Protein expression by reverse-phase protein arrays.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Omics: Virome analysis using RNAseq.
Sequence variations TP53 p.Arg248Gln (c.743G>A) (PubMed=1915267).
HLA typing Source: PubMed=25960936
Class I
HLA-AA*32:01,11:01
HLA-BB*49:01,35:01
HLA-CC*04:01,07:01
Class II
HLA-DQDQA1*01:01,01:01
DQB1*05:03,05:03
HLA-DRDRB1*14:01,01:01
Disease Burkitt lymphoma (NCIt: C2912)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children:
CVCL_9667 (BL41-K3)
Originate from same individual CVCL_IV22 ! IARC-171
Sex of cell Male
Age at sampling 8Y
Category Cancer cell line
STR profile Source(s): Cosmic-CLP; DSMZ

Markers:
AmelogeninX,Y
CSF1PO10,11 (Cosmic-CLP)
9,10,11 (DSMZ)
D13S3178,11
D16S53912
D5S81811,13
D7S8209,11
TH017,9.3
TPOX7,8
vWA14,18
Web pages http://tcpaportal.org/mclp/
Publications

PubMed=3934070
Lenoir G.M., Vuillaume M., Bonnardel C.
The use of lymphomatous and lymphoblastoid cell lines in the study of Burkitt's lymphoma.
IARC Sci. Publ. 60:309-318(1985)

PubMed=2825176; DOI=10.1073/pnas.84.22.8060
Calender A., Billaud M., Aubry J.-P., Banchereau J., Vuillaume M., Lenoir G.M.
Epstein-Barr virus (EBV) induces expression of B-cell activation markers on in vitro infection of EBV-negative B-lymphoma cells.
Proc. Natl. Acad. Sci. U.S.A. 84:8060-8064(1987)

PubMed=3027441; DOI=10.1093/jnci/78.2.235
Cohen J.H.M., Revillard J.-P., Magaud J.-P., Lenoir G.M., Vuillaume M., Manel A.-M., Vincent C., Bryon P.-A.
B-cell maturation stages of Burkitt's lymphoma cell lines according to Epstein-Barr virus status and type of chromosome translocation.
J. Natl. Cancer Inst. 78:235-242(1987)

PubMed=1915267
Farrell P.J., Allan G.J., Shanahan F., Vousden K.H., Crook T.
p53 is frequently mutated in Burkitt's lymphoma cell lines.
EMBO J. 10:2879-2887(1991)

PubMed=8547074; DOI=10.1111/j.1365-2141.1995.tb05302.x
Siebert R., Willers C.P., Schramm A., Fossa A., Dresen I.M.G., Uppenkamp M., Nowrousian M.R., Seeber S., Opalka B.
Homozygous loss of the MTS1/p16 and MTS2/p15 genes in lymphoma and lymphoblastic leukaemia cell lines.
Br. J. Haematol. 91:350-354(1995)

PubMed=8558920
Dirks W.G., Zaborski M., Jager K., Challier C., Shiota M., Quentmeier H., Drexler H.G.
The (2;5)(p23;q35) translocation in cell lines derived from malignant lymphomas: absence of t(2;5) in Hodgkin-analogous cell lines.
Leukemia 10:142-149(1996)

PubMed=9473234
Klangby U., Okan I., Magnusson K.P., Wendland M., Lind P., Wiman K.G.
p16/INK4a and p15/INK4b gene methylation and absence of p16/INK4a mRNA and protein expression in Burkitt's lymphoma.
Blood 91:1680-1687(1998)

PubMed=9973220
Gutierrez M.I., Cherney B., Hussain A., Mostowski H., Tosato G., Magrath I.T., Bhatia K.
Bax is frequently compromised in Burkitt's lymphomas with irreversible resistance to Fas-induced apoptosis.
Cancer Res. 59:696-703(1999)

PubMed=16960149; DOI=10.1182/blood-2006-06-026500
Mestre-Escorihuela C., Rubio-Moscardo F., Richter J.A., Siebert R., Climent J., Fresquet V., Beltran E., Agirre X., Marugan I., Marin M., Rosenwald A., Sugimoto K.-J., Wheat L.M., Karran E.L., Garcia J.F., Sanchez L., Prosper F., Staudt L.M., Pinkel D., Dyer M.J.S., Martinez-Climent J.A.
Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas.
Blood 109:271-280(2007)

PubMed=19358282; DOI=10.1002/ijc.24351
Inagaki A., Ishida T., Yano H., Ishii T., Kusumoto S., Ito A., Ri M., Mori F., Ding J., Komatsu H., Iida S., Ueda R.
Expression of the ULBP ligands for NKG2D by B-NHL cells plays an important role in determining their susceptibility to rituximab-induced ADCC.
Int. J. Cancer 125:212-221(2009)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L., Winckler W., Reich M., Li N., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=22885699; DOI=10.1038/nature11378
Schmitz R., Young R.M., Ceribelli M., Jhavar S., Xiao W., Zhang M., Wright G., Shaffer A.L., Hodson D.J., Buras E., Liu X., Powell J., Yang Y., Xu W., Zhao H., Kohlhammer H., Rosenwald A., Kluin P., Muller-Hermelink H.K., Ott G., Gascoyne R.D., Connors J.M., Rimsza L.M., Campo E., Jaffe E.S., Delabie J., Smeland E.B., Ogwang M.D., Reynolds S.J., Fisher R.I., Braziel R.M., Tubbs R.R., Cook J.R., Weisenburger D.D., Chan W.C., Pittaluga S., Wilson W., Waldmann T.A., Rowe M., Mbulaiteye S.M., Rickinson A.B., Staudt L.M.
Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics.
Nature 490:116-120(2012)

PubMed=25960936; DOI=10.4161/21624011.2014.954893
Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.
A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines.
OncoImmunology 3:E954893-E954893(2014)

PubMed=25355872; DOI=10.1128/JVI.02570-14
Cao S., Strong M.J., Wang X., Moss W.N., Concha M., Lin Z., O'Grady T., Baddoo M., Fewell C., Renne R., Flemington E.K.
High-throughput RNA sequencing-based virome analysis of 50 lymphoma cell lines from the Cancer Cell Line Encyclopedia project.
J. Virol. 89:713-729(2015)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P., Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

Cross-references
Cell line collections DSMZ; ACC-160
NCBI_Iran; C493
Cell line databases/resources CLDB; cl459
CCLE; BL41_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
Cosmic-CLP; 910706
GDSC; 910706
LINCS_LDP; LCL-2028
Ontologies BTO; BTO:0003854
CLO; CLO_0001987
Biological sample resources BioSample; SAMN03473420
Chemistry resources ChEMBL-Cells; CHEMBL3308526
ChEMBL-Targets; CHEMBL2366173
Gene expression databases ArrayExpress; E-MTAB-2770
ArrayExpress; E-MTAB-3610
GEO; GSM119535
GEO; GSM862863
GEO; GSM862864
GEO; GSM862865
GEO; GSM862866
GEO; GSM886889
GEO; GSM887954
GEO; GSM1669625
Other Wikidata; Q54797155
Polymorphism and mutation databases Cosmic; 910706
Cosmic; 931099
Cosmic; 991550
Cosmic; 1086324
Cosmic; 1818339
Cosmic; 2297031
Cosmic; 2361383